Journal Article

Orally delivered rutin in lipid-based nano-formulation exerts strong antithrombotic effects by protein disulfide isomerase inhibition

Liu, Peiwen, Liu, Yurong, Zhou, Yang, Chen, Dan, Jiang, Longguang, Huang, Mingdong, Yuan, Cai

2022

Overview

Thrombosis occurs in both macrovasculature and microvasculature, causing various cardio-cerebral vascular diseases. The lack of effective and safe antithrombotic drugs leads to a public health crisis. Mounting evidence suggests that protein disulfide isomerase (PDI) plays a critical role in the initial stage of thrombus formation, motivating the research of the feasibility of PDI inhibitors as novel anti-thrombotics. Rutin, one of the most potent PDI inhibitors, was reported to suppress platelet aggregation and thrombosis in animal models, but further studies and clinical translation were restricted due to its low aqueous solubility and oral bioavailability. In this work, we fabricated rutin-loaded lipid-based nano-formulation (NanoR) and characterized their physical-chemical properties, release profiles, pharmacokinetic process, and pharmacodynamic function against thrombosis in macrovessels and microvessels. NanoR provided increased solubility and dissolution of rutin to achieve earlier T max and higher C max than the sodium salt of rutin (NaR) after oral gavage. Ex vivo studies demonstrated that NanoR significantly inhibited thrombin generation and clot formation in the plasma of mice. Importantly, such effect was reversed by exogenous recombinant PDI, demonstrating the specificity of the NanoR. In direct current-induced arterial thrombosis model and ferric chloride-induced microvascular thrombosis model, NanoR exhibited greatly enhanced antithrombotic activity compared with NaR. NanoR also showed good safety performance according to tail bleeding assay, global coagulation tests, and histological analysis. Overall, our current results indicated that NanoR offers a promising antithrombotic treatment with potential for clinical translation.

• Publisher: Taylor & Francis,Taylor & Francis Ltd,Taylor & Francis Group
• Subject: Animals / antithrombotic drug / Bioavailability / Biomedical engineering / Blood clots / Blood Platelets - metabolism / Drug delivery systems / Engineering research / Fibrinolytic Agents - pharmacology / Fibrinolytic Agents - therapeutic use / Laboratory animals / Lipids / Mice / microcirculation / protein disulfide isomerase / Protein Disulfide-Isomerases - metabolism / Protein Disulfide-Isomerases - therapeutic use / Proteins / Rutin / Rutin - pharmacology / self-nanoemulsifying drug delivery system / Surfactants / Thrombosis / Thrombosis - drug therapy